Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
Florian CastetCatherine E WilloughbyPhilipp K HaberJosep M LlovetPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.See related article by Casak et al., p. 1836.
Keyphrases